Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Evaluation of Image and Molecular Fingerprint Characterization to Guide Treatment With Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma

NCT03958669 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT03958669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03958669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Evaluation of Image and Molecular Fingerprint Characterization to Guide Treatment With Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma
Lead sponsor
University Hospital Tuebingen
Phase
Observational
Overall status
Terminated
Start date
November 1, 2019
Completion date
May 31, 2023
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, sorafenib